Dublin, Ireland (PRWEB) March 20, 2013
As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of decreasing hormone levels have come to the forefront as a quality-of-life issue for patients and their families.
For the past two decades, the healthcare industry has responded to this clinical need by developing, testing and marketing hormone replacement therapy (HRT) products. Because of their ease-of-use and dosing characteristics, drug developers are continuing to turn to transdermal delivery systems for HRT products. There are more than 40 million post-menopausal women in the United States alone, and this group is expected to grow by 50% by 2020. With the aging of the population worldwide, conditions and diseases such as menopause, osteoporosis and heart disease, which may benefit from hormone replacement therapy, are expected to become significantly more prevalent. The industry continues to attract interest in the form of new participants and products.
While the global market continues to be dominated by the FDA-approved HRT products of major pharmaceutical firms, regional markets are a bit more competitive, and present unique challenges to transdermal HRT sector participants.
- Analyzes and evaluates the global market opportunity for transdermal hormone replacement and assesses the probable impact of evolving regulatory, economic and demand factors
- Assesses transdermal products approved or in development for the delivery of therapeutic hormones
- Provides detailed descriptions of hormone replacement treatment segments, market factors, and business strategies
- Forecasts transdermal hormone replacement product demand to 2016 by geographic region and product segment
- Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners
For more information please visit http://www.researchandmarkets.com/research/c4mvd9/transdermal
Research and Markets
Laura Wood, Senior Manager.